TACE-HAIC+Atezolizumab+Bevacizumab for Unresectable HCC: a Phase 2 Clinical Trial
Status:
Recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
Transartial chemobolization plus hepatic artery infusion chemotherapy showed performance for
unresectable hepatocellular carcinoma (HCC). Whether the additional of atezolizumab plus
bevacizumab will improve the response rate for those patients is still unknown. This phase 2
clinical trial aims to investigate the objective response rate for unresectable
hepatocellular carcinoma.